112 related articles for article (PubMed ID: 12357871)
1. [Novel therapeutic approach to amyloidosis: no implications as yet for patients with Alzheimer's disease].
Lemstra AW; Eikelenboom P; Meijer EW; van Gool WA
Ned Tijdschr Geneeskd; 2002 Sep; 146(37):1720-3. PubMed ID: 12357871
[TBL] [Abstract][Full Text] [Related]
2. Targeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis.
Pepys MB; Herbert J; Hutchinson WL; Tennent GA; Lachmann HJ; Gallimore JR; Lovat LB; Bartfai T; Alanine A; Hertel C; Hoffmann T; Jakob-Roetne R; Norcross RD; Kemp JA; Yamamura K; Suzuki M; Taylor GW; Murray S; Thompson D; Purvis A; Kolstoe S; Wood SP; Hawkins PN
Nature; 2002 May; 417(6886):254-9. PubMed ID: 12015594
[TBL] [Abstract][Full Text] [Related]
3. Drug targets for amyloidosis.
Kolstoe SE; Wood SP
Biochem Soc Trans; 2010 Apr; 38(2):466-70. PubMed ID: 20298204
[TBL] [Abstract][Full Text] [Related]
4. [At last new light for the treatment of amyloidosis].
Pettersson T
Duodecim; 2003; 119(12):1097-8. PubMed ID: 12868354
[No Abstract] [Full Text] [Related]
5. Therapeutic strategies for human amyloid diseases.
Sacchettini JC; Kelly JW
Nat Rev Drug Discov; 2002 Apr; 1(4):267-75. PubMed ID: 12120278
[TBL] [Abstract][Full Text] [Related]
6. New insights into the mechanisms of protein misfolding and aggregation in amyloidogenic diseases derived from pressure studies.
Foguel D; Silva JL
Biochemistry; 2004 Sep; 43(36):11361-70. PubMed ID: 15350123
[TBL] [Abstract][Full Text] [Related]
7. Amyloidosis: a clinico-pathophysiological synopsis.
Hirschfield GM
Semin Cell Dev Biol; 2004 Feb; 15(1):39-44. PubMed ID: 15036205
[TBL] [Abstract][Full Text] [Related]
8. Sustained pharmacological depletion of serum amyloid P component in patients with systemic amyloidosis.
Gillmore JD; Tennent GA; Hutchinson WL; Gallimore JR; Lachmann HJ; Goodman HJ; Offer M; Millar DJ; Petrie A; Hawkins PN; Pepys MB
Br J Haematol; 2010 Mar; 148(5):760-7. PubMed ID: 20064157
[TBL] [Abstract][Full Text] [Related]
9. Experimental investigation of protein folding and misfolding.
Dobson CM
Methods; 2004 Sep; 34(1):4-14. PubMed ID: 15283911
[TBL] [Abstract][Full Text] [Related]
10. Development of tau aggregation inhibitors for Alzheimer's disease.
Bulic B; Pickhardt M; Schmidt B; Mandelkow EM; Waldmann H; Mandelkow E
Angew Chem Int Ed Engl; 2009; 48(10):1740-52. PubMed ID: 19189357
[TBL] [Abstract][Full Text] [Related]
11. The structural basis of protein folding and its links with human disease.
Dobson CM
Philos Trans R Soc Lond B Biol Sci; 2001 Feb; 356(1406):133-45. PubMed ID: 11260793
[TBL] [Abstract][Full Text] [Related]
12. Preferential association of serum amyloid P component with fibrillar deposits in familial British and Danish dementias: similarities with Alzheimer's disease.
Rostagno A; Lashley T; Ng D; Meyerson J; Braendgaard H; Plant G; Bojsen-Møller M; Holton J; Frangione B; Revesz T; Ghiso J
J Neurol Sci; 2007 Jun; 257(1-2):88-96. PubMed ID: 17374542
[TBL] [Abstract][Full Text] [Related]
13. Metastable, partially folded states in the productive folding and in the misfolding and amyloid aggregation of proteins.
Ferreira ST; De Felice FG; Chapeaurouge A
Cell Biochem Biophys; 2006; 44(3):539-48. PubMed ID: 16679542
[TBL] [Abstract][Full Text] [Related]
14. Unraveling the mysteries of protein folding and misfolding.
Ecroyd H; Carver JA
IUBMB Life; 2008 Dec; 60(12):769-74. PubMed ID: 18767168
[TBL] [Abstract][Full Text] [Related]
15. A high-throughput screen for compounds that inhibit aggregation of the Alzheimer's peptide.
Kim W; Kim Y; Min J; Kim DJ; Chang YT; Hecht MH
ACS Chem Biol; 2006 Aug; 1(7):461-9. PubMed ID: 17168524
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of beta-amyloid peptide aggregation and neurotoxicity by alpha-d-mannosylglycerate, a natural extremolyte.
Ryu J; Kanapathipillai M; Lentzen G; Park CB
Peptides; 2008 Apr; 29(4):578-84. PubMed ID: 18304694
[TBL] [Abstract][Full Text] [Related]
17. Alzheimer's disease therapeutics: new approaches to an ageing problem.
Small DH; Losic D; Martin LL; Turner BJ; Friedhuber A; Aguilar MI
IUBMB Life; 2004 Apr; 56(4):203-8. PubMed ID: 15230347
[TBL] [Abstract][Full Text] [Related]
18. Drug Insight: emerging therapies for amyloidosis.
Gillmore JD; Hawkins PN
Nat Clin Pract Nephrol; 2006 May; 2(5):263-70. PubMed ID: 16932439
[TBL] [Abstract][Full Text] [Related]
19. Protein misfolding in neurodegenerative diseases.
Agorogiannis EI; Agorogiannis GI; Papadimitriou A; Hadjigeorgiou GM
Neuropathol Appl Neurobiol; 2004 Jun; 30(3):215-24. PubMed ID: 15175075
[TBL] [Abstract][Full Text] [Related]
20. Diseases of protein aggregation and the hunt for potential pharmacological agents.
Wang SS; Wu JW; Yamamoto S; Liu HS
Biotechnol J; 2008 Feb; 3(2):165-92. PubMed ID: 18034432
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
